Monoclonal Antibody to Nuclear Receptor Coactivator 3 (NCOA3)
Code | Size | Price |
---|
MAE798Hu21-20ul | 20ul | £90.00 |
Quantity:
MAE798Hu21-100ul | 100ul | £169.00 |
Quantity:
MAE798Hu21-200ul | 200ul | £229.00 |
Quantity:
MAE798Hu21-1ml | 1ml | £526.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
RAC3; ACTR; AIB1; CAGH16; CTG26; SRC3; TNRC14; TNRC16; TRAM1; pCIP; Amplified In Breast 1; Steroid Receptor Coactivator-3 ; Thyroid Hormone Receptor Activator Molecule 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Nuclear Receptor Coactivator 3
Potency (Clone Number):
D3
Reactivity:
Po;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Nuclear Receptor Coactivator 3 (NCOA3) | RPE798Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||